$APDN
APPLIED DNA SCIENCES INC

2023 Q4 Form 10-K Financial Statement

#000141057823002615 Filed on December 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023
Revenue $891.2K $779.7K $13.37M
YoY Change -83.07% -78.09% -26.43%
Cost Of Revenue $660.1K $700.7K $7.834M
YoY Change -77.12% -77.7% -40.27%
Gross Profit $231.1K $79.00K $5.533M
YoY Change -90.28% -81.04% 9.49%
Gross Profit Margin 25.93% 10.13% 41.39%
Selling, General & Admin $3.084M $3.311M $12.75M
YoY Change 17.48% -14.52% -15.54%
% of Gross Profit 1334.66% 4191.03% 230.45%
Research & Development $935.8K $938.9K $3.735M
YoY Change -3.65% 2.85% -4.86%
% of Gross Profit 404.94% 1188.49% 67.5%
Depreciation & Amortization $299.0K $332.2K $1.362M
YoY Change -11.79% 1.39% 5.56%
% of Gross Profit 129.36% 420.57% 24.62%
Operating Expenses $4.020M $4.250M $16.49M
YoY Change 11.77% -11.21% -13.33%
Operating Profit -$3.789M -$4.171M -$10.95M
YoY Change 210.84% -4.55% -21.59%
Interest Expense $33.32K $41.22K $75.33K
YoY Change 802.98% 2865.47% 946.25%
% of Operating Profit
Other Income/Expense, Net -$13.54K $514.0K $642.00
YoY Change -253.04% -86.12% -101.36%
Pretax Income -$1.130M -$3.616M -$10.02M
YoY Change -70.6% 444.07% 21.2%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.105M -$3.592M -$9.947M
YoY Change -71.25% 441.64% 20.31%
Net Earnings / Revenue -124.01% -460.7% -74.41%
Basic Earnings Per Share -$0.09 -$0.76
Diluted Earnings Per Share -$0.09 -$0.26 -$0.76
COMMON SHARES
Basic Shares Outstanding 13.69M 13.66M 13.08M
Diluted Shares Outstanding 13.67M 13.08M

Balance Sheet

Concept 2023 Q4 2023 Q3 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.359M $7.152M $7.152M
YoY Change -73.91% -53.0% -53.0%
Cash & Equivalents $3.359M $7.152M $7.152M
Short-Term Investments
Other Short-Term Assets $403.0K $389.2K $389.2K
YoY Change -56.42% -63.21% -63.21%
Inventory $377.3K $330.0K $330.0K
Prepaid Expenses
Receivables $450.8K $255.5K $255.5K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.590M $8.127M $8.127M
YoY Change -74.96% -59.25% -59.25%
LONG-TERM ASSETS
Property, Plant & Equipment $539.3K $838.3K $2.076M
YoY Change -71.09% -62.29% -6.61%
Goodwill
YoY Change
Intangibles $2.699M $2.699M
YoY Change
Long-Term Investments
YoY Change
Other Assets $967.6K $750.0K $750.0K
YoY Change 877.42% 657.58% 657.58%
Total Long-Term Assets $5.323M $5.525M $5.525M
YoY Change 170.93% 137.94% 137.94%
TOTAL ASSETS
Total Short-Term Assets $4.590M $8.127M $8.127M
Total Long-Term Assets $5.323M $5.525M $5.525M
Total Assets $9.913M $13.65M $13.65M
YoY Change -51.16% -38.69% -38.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.017M $1.072M $1.072M
YoY Change -49.73% -38.53% -38.53%
Accrued Expenses $1.517M $1.697M $1.697M
YoY Change 46.86% -9.63% -9.63%
Deferred Revenue $54.04K $76.44K
YoY Change -80.27% -86.44%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.588M $2.845M $2.845M
YoY Change -22.28% -32.01% -32.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.513M $5.250M $5.250M
YoY Change -67.82% 1.52% 1.52%
Total Long-Term Liabilities $2.513M $5.250M $5.250M
YoY Change -67.82% 1.52% 1.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.588M $2.845M $2.845M
Total Long-Term Liabilities $2.513M $5.250M $5.250M
Total Liabilities $5.785M $8.779M $8.700M
YoY Change -48.07% -6.17% -6.98%
SHAREHOLDERS EQUITY
Retained Earnings -$303.6M -$302.4M
YoY Change 2.46% 3.4%
Common Stock $307.9M $307.4M
YoY Change 0.77% 0.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.232M $4.951M $4.951M
YoY Change
Total Liabilities & Shareholders Equity $9.913M $13.65M $13.65M
YoY Change -51.16% -38.69% -38.69%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023
OPERATING ACTIVITIES
Net Income -$1.105M -$3.592M -$9.947M
YoY Change -71.25% 441.64% 20.31%
Depreciation, Depletion And Amortization $299.0K $332.2K $1.362M
YoY Change -11.79% 1.39% 5.56%
Cash From Operating Activities -$3.758M -$2.678M -$6.218M
YoY Change 57.68% -17.83% -30.74%
INVESTING ACTIVITIES
Capital Expenditures $1.061M $78.45K
YoY Change -537.16% -83.98%
Acquisitions
YoY Change
Other Investing Activities $135.0K $45.00K
YoY Change
Cash From Investing Activities -$925.8K -$1.096M
YoY Change 281.53% 123.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -35.08K 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -3.758M -2.678M -6.218M
Cash From Investing Activities -925.8K -1.096M
Cash From Financing Activities -35.08K 0.000 0.000
Net Change In Cash -3.793M -3.603M -7.313M
YoY Change 62.21% -134.21% -184.45%
FREE CASH FLOW
Cash From Operating Activities -$3.758M -$2.678M -$6.218M
Capital Expenditures $1.061M $78.45K
Free Cash Flow -$3.738M -$6.296M
YoY Change 23.96% -33.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000744452
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Registrant Name
EntityRegistrantName
APPLIED DNA SCIENCES INC
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12908520
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13658520
CY2023Q3 apdn Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q3 apdn Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q3 apdn Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2023Q3 apdn Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36745
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
76435
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-2262718
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
50 Health Sciences Drive
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Stony Brook
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11790
CY2023 dei City Area Code
CityAreaCode
631
CY2023 dei Local Phone Number
LocalPhoneNumber
240-8800
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023 dei Trading Symbol
TradingSymbol
APDN
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Public Float
EntityPublicFloat
14400000
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13687420
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Location
AuditorLocation
Melville, NY
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15215285
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
330853
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
255502
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3067544
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2022Q3 us-gaap Inventory Net
InventoryNet
602244
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
389241
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1058056
CY2023Q3 us-gaap Assets Current
AssetsCurrent
8126570
CY2022Q3 us-gaap Assets Current
AssetsCurrent
19943129
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
838270
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2222988
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1237762
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
98997
CY2023Q3 us-gaap Assets
Assets
13651577
CY2022Q3 us-gaap Assets
Assets
22265114
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3621751
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498598
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
563557
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2845421
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4185308
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
194000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
739162
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2023Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
4285000
CY2022Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
5139400
CY2023Q3 us-gaap Liabilities
Liabilities
8779165
CY2022Q3 us-gaap Liabilities
Liabilities
9356175
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13658520
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12908520
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
13659
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
12909
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307384647
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
305399008
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302447147
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292500088
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4951159
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12911829
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-78747
CY2022Q3 us-gaap Minority Interest
MinorityInterest
-2890
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13651577
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22265114
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13367443
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18168677
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
7834011
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
13115037
CY2023 us-gaap Gross Profit
GrossProfit
5533432
CY2022 us-gaap Gross Profit
GrossProfit
5053640
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12751644
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15097360
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3735078
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3926043
CY2023 us-gaap Operating Expenses
OperatingExpenses
16486722
CY2022 us-gaap Operating Expenses
OperatingExpenses
19023403
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-10953290
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-13969763
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
75332
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7200
CY2022 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-1668112
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-854400
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17999521
CY2022 apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
10591600
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
642
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47305
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10022916
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8270059
CY2023 us-gaap Profit Loss
ProfitLoss
-10022916
CY2022 us-gaap Profit Loss
ProfitLoss
-8270059
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-75857
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2168
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9947059
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-8267891
CY2022 apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
110105
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9947059
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8377996
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13075416
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13075416
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8967704
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8967704
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11112946
CY2022 apdn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3700075
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2802879
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2518665
CY2022 apdn Shares Issued In Public Offering
SharesIssuedInPublicOffering
-744433
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
300000
CY2022 us-gaap Profit Loss
ProfitLoss
-8270059
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1033889
CY2023 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
952500
CY2023 us-gaap Profit Loss
ProfitLoss
-10022916
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2023 us-gaap Profit Loss
ProfitLoss
-10022916
CY2022 us-gaap Profit Loss
ProfitLoss
-8270059
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1362249
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1290480
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6083
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-854400
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17999521
CY2022 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-1668112
CY2022 apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
10591600
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1033889
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2518665
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-239043
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
269451
CY2023 apdn Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
62000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3051083
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
532957
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-272217
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-767689
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-767812
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
493220
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1351363
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
930497
CY2023 apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-293122
CY2022 apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
282557
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6217677
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8976706
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1062360
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78448
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
489553
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1095808
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-489553
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3700075
CY2022 apdn Net Proceeds From Sale Of Common Stock And Warrants
NetProceedsFromSaleOfCommonStockAndWarrants
14426521
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18126596
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7313485
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8660337
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6554948
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2022 apdn Deemed Dividend Warrant Modifications
DeemedDividendWarrantModifications
110105
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
CY2022 apdn Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
25939000
CY2022 apdn Fair Value Of Warrants Exercised
FairValueOfWarrantsExercised
2802879
CY2023 us-gaap Stock Issued1
StockIssued1
952500
CY2023 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
684115
CY2022 apdn Issuance Of Stock Options Issued For Payment Of Accrued Bonus
IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus
300000
CY2023 apdn Effective Income Tax Rate Reconciliation Permanent Differences Related Warrants Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesRelatedWarrantsPercent
0.0180
CY2022 apdn Effective Income Tax Rate Reconciliation Permanent Differences Related Warrants Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesRelatedWarrantsPercent
0.1460
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0197
CY2023 apdn Number Of Primary Markets That Use Company S Technologies
NumberOfPrimaryMarketsThatUseCompanySTechnologies
3
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302447147
CY2023 us-gaap Profit Loss
ProfitLoss
-10022916
CY2023 apdn Net Cash Used In Operating Activities
NetCashUsedInOperatingActivities
6217677
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of the financial statements in conformity with Accounting Principles Generally Accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.</p>
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13367443
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18168677
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
345480
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
31061
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15215285
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0170
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
330853
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4250471
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4292940
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3412201
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2069952
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
838270
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2222988
CY2023 us-gaap Depreciation
Depreciation
1362249
CY2022 us-gaap Depreciation
Depreciation
1290480
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7707465
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8377018
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents, restricted cash and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of September 30, 2023, the Company had cash and cash equivalents of approximately $6.9 million in excess of the FDIC insurance limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from sale of products and services for the  fiscal year ended September 30, 2023 included an aggregate of 65% and 14%, respectively from two customers within the MDx Testing Services segment. 65% and 58% of the revenues earned for the fiscal years ended September 30, 2023 and 2022, respectively was derived from the COVID-19 testing contract with CUNY that terminated during June 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from sale of products and services for the fiscal year ended September 30, 2022 included an aggregate of 58% from one customer within the MDx Testing Services segment. Three customers accounted for 60% of the Company’s accounts receivable at September 30, 2023 and two customers accounted for 89% of the Company’s accounts receivable at September 30, 2022.</p>
CY2023Q3 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
6900000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3735078
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3926043
CY2023 us-gaap Advertising Expense
AdvertisingExpense
185115
CY2022 us-gaap Advertising Expense
AdvertisingExpense
293395
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0128
CY2023 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2022 apdn Offering Costs Incurred
OfferingCostsIncurred
1766170
CY2022 apdn Charged To Additional Paid In Capital
ChargedToAdditionalPaidInCapital
98058
CY2022 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-1668112
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
212079
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
471947
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
19859
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
55817
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
98089
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
74480
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2022Q3 us-gaap Inventory Net
InventoryNet
602244
CY2023Q3 apdn Threshold Period For Assets Yield On Net Sales Revenue To Cover Cost Of Acquisition
ThresholdPeriodForAssetsYieldOnNetSalesRevenueToCoverCostOfAcquisition
P10Y
CY2023Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.50
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0993
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0383
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1072161
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1744105
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1138235
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1458661
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59992
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
418985
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3621751
CY2023 apdn Beneficial Ownership Limitation Percentage
BeneficialOwnershipLimitationPercentage
0.0499
CY2023 apdn Beneficial Ownership Limitation Percentage At Option Of Holder
BeneficialOwnershipLimitationPercentageAtOptionOfHolder
0.0999
CY2023 apdn Period Of Prior Notice To Increase Beneficial Ownership Percentage Limitation
PeriodOfPriorNoticeToIncreaseBeneficialOwnershipPercentageLimitation
P61D
CY2023 apdn Beneficial Ownership Limitation Percentage At Option Of Holder
BeneficialOwnershipLimitationPercentageAtOptionOfHolder
0.0999
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.80
CY2022 apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
110105
CY2023 apdn Minimum Percentage Of Beneficial Ownership Limitation Right To Exercise Warrants
MinimumPercentageOfBeneficialOwnershipLimitationRightToExerciseWarrants
0.0499
CY2023 apdn Percentage On Number Of Shares For Beneficial Ownership Limitation Right To Exercise Warrants
PercentageOnNumberOfSharesForBeneficialOwnershipLimitationRightToExerciseWarrants
0.0999
CY2023 apdn Notice Period To Increase Percentage Of Beneficial Ownership Limitations
NoticePeriodToIncreasePercentageOfBeneficialOwnershipLimitations
P61D
CY2023 apdn Percentage On Number Of Shares For Beneficial Ownership Limitation Right To Exercise Warrants
PercentageOnNumberOfSharesForBeneficialOwnershipLimitationRightToExerciseWarrants
0.0999
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7313963
CY2022Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.68
CY2023 apdn Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
2093375
CY2023 apdn Weighted Average Price Per Share Warrant Cancelled Or Expired
WeightedAveragePricePerShareWarrantCancelledOrExpired
-4.12
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5220588
CY2023 apdn Share Price Two
SharePriceTwo
1.27
CY2022 apdn Share Price Two
SharePriceTwo
5.55
CY2023 apdn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceTwo
1.27
CY2022 apdn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceTwo
594
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M28D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.57
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.43
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0364
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0118
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1033889
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2518665
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
716898
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P2Y1M28D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.20
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.84
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
282640
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
282640
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
282640
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0501
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3249000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2781000
CY2023 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-3249000
CY2022 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-2781000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1161000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-852000
CY2023 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-1161000
CY2022 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-852000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-121000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
11000
CY2023 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
0
CY2022 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4531000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3622000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 apdn Effective Income Tax Rate Reconciliation Federal Benefit
EffectiveIncomeTaxRateReconciliationFederalBenefit
0.01
CY2022 apdn Effective Income Tax Rate Reconciliation Federal Benefit
EffectiveIncomeTaxRateReconciliationFederalBenefit
0.01
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0956
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0620
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0176
CY2023 apdn Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRatePercent
0.0167
CY2022 apdn Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRatePercent
0.0156
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4545
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4388
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2023Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
993000
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
847000
CY2023Q3 apdn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
440000
CY2022Q3 apdn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
113000
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25250000
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22872000
CY2023Q3 apdn Deferred Tax Assets Impairment Intangible Assets
DeferredTaxAssetsImpairmentIntangibleAssets
227000
CY2022Q3 apdn Deferred Tax Assets Impairment Intangible Assets
DeferredTaxAssetsImpairmentIntangibleAssets
205000
CY2023Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
726000
CY2022Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
0
CY2023Q3 apdn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
342000
CY2022Q3 apdn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
0
CY2023Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3060000
CY2022Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2055000
CY2023Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
324000
CY2022Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
397000
CY2023Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
31362000
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26489000
CY2023Q3 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
684000
CY2022Q3 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
0
CY2023Q3 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
342000
CY2022Q3 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
0
CY2023Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1026000
CY2022Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31020000
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26489000
CY2023Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
684000
CY2022Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
101526000
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
56892000
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
60374000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4531000
CY2023Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2539000
CY2023Q3 apdn Deferred Tax Assets Tax Credit Carryforwards State Investment
DeferredTaxAssetsTaxCreditCarryforwardsStateInvestment
475000
CY2013Q2 apdn Area Of Property Under Operating Lease
AreaOfPropertyUnderOperatingLease
30000
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2023Q1 apdn Area Of Laboratory Space
AreaOfLaboratorySpace
2500
CY2017Q4 apdn Lease For Satellite Testing
LeaseForSatelliteTesting
1108
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 apdn Base Rent During Initial Lease Term
BaseRentDuringInitialLeaseTerm
6500
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
663513
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
587346
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
657241
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
587346
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6272
CY2023 us-gaap Lease Cost
LeaseCost
663513
CY2022 us-gaap Lease Cost
LeaseCost
587346
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
390889
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
586334
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
586334
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
195445
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1368113
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
130351
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1237762
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13367443
CY2023 us-gaap Gross Profit
GrossProfit
5533432
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18168677
CY2022 us-gaap Gross Profit
GrossProfit
5053640
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
75332
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7200
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-854400
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17999521
CY2022 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-1668112
CY2022 apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
10591600
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
642
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47305
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10022916
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8270059
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13367443
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18168677

Files In Submission

Name View Source Status
0001410578-23-002615-index-headers.html Edgar Link pending
0001410578-23-002615-index.html Edgar Link pending
0001410578-23-002615.txt Edgar Link pending
0001410578-23-002615-xbrl.zip Edgar Link pending
apdn-20230930.xsd Edgar Link pending
apdn-20230930x10k.htm Edgar Link pending
apdn-20230930xex21d1.htm Edgar Link pending
apdn-20230930xex23d1.htm Edgar Link pending
apdn-20230930xex31d1.htm Edgar Link pending
apdn-20230930xex31d2.htm Edgar Link pending
apdn-20230930xex32d1.htm Edgar Link pending
apdn-20230930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
apdn-20230930_cal.xml Edgar Link unprocessable
apdn-20230930_def.xml Edgar Link unprocessable
apdn-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apdn-20230930_pre.xml Edgar Link unprocessable
apdn-20230930x10k_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending